This pipeline uses various statistical tests to identify RPPAs whose expression levels correlated to selected clinical features.
Testing the association between 175 genes and 9 clinical features across 53 samples, statistically thresholded by Q value < 0.05, 1 clinical feature related to at least one genes.
-
1 gene correlated to 'NUMBER.OF.LYMPH.NODES'.
-
BAK1|BAK-R-C
-
No genes correlated to 'Time to Death', 'AGE', 'GENDER', 'KARNOFSKY.PERFORMANCE.SCORE', 'NUMBERPACKYEARSSMOKED', 'DISTANT.METASTASIS', 'LYMPH.NODE.METASTASIS', and 'NEOPLASM.DISEASESTAGE'.
Complete statistical result table is provided in Supplement Table 1
Clinical feature | Statistical test | Significant genes | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=0 | ||||
AGE | Spearman correlation test | N=0 | ||||
GENDER | t test | N=0 | ||||
KARNOFSKY PERFORMANCE SCORE | Spearman correlation test | N=0 | ||||
NUMBERPACKYEARSSMOKED | Spearman correlation test | N=0 | ||||
DISTANT METASTASIS | ANOVA test | N=0 | ||||
LYMPH NODE METASTASIS | ANOVA test | N=0 | ||||
NUMBER OF LYMPH NODES | Spearman correlation test | N=1 | higher number.of.lymph.nodes | N=0 | lower number.of.lymph.nodes | N=1 |
NEOPLASM DISEASESTAGE | ANOVA test | N=0 |
Time to Death | Duration (Months) | 0.4-118.9 (median=8.3) |
censored | N = 32 | |
death | N = 20 | |
Significant markers | N = 0 |
AGE | Mean (SD) | 67.31 (9.8) |
Significant markers | N = 0 |
GENDER | Labels | N |
FEMALE | 21 | |
MALE | 32 | |
Significant markers | N = 0 |
No gene related to 'KARNOFSKY.PERFORMANCE.SCORE'.
KARNOFSKY.PERFORMANCE.SCORE | Mean (SD) | 80 (17) |
Score | N | |
40 | 1 | |
60 | 1 | |
70 | 1 | |
80 | 1 | |
90 | 7 | |
Significant markers | N = 0 |
NUMBERPACKYEARSSMOKED | Mean (SD) | 32.15 (18) |
Significant markers | N = 0 |
DISTANT.METASTASIS | Labels | N |
M0 | 41 | |
M1 | 2 | |
MX | 10 | |
Significant markers | N = 0 |
LYMPH.NODE.METASTASIS | Labels | N |
N0 | 33 | |
N1 | 5 | |
N2 | 11 | |
N3 | 1 | |
NX | 2 | |
Significant markers | N = 0 |
NUMBER.OF.LYMPH.NODES | Mean (SD) | 1.53 (3) |
Significant markers | N = 1 | |
pos. correlated | 0 | |
neg. correlated | 1 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
BAK1|BAK-R-C | -0.6234 | 8.197e-05 | 0.0143 |
-
Expresson data file = BLCA-TP.rppa.txt
-
Clinical data file = BLCA-TP.clin.merged.picked.txt
-
Number of patients = 53
-
Number of genes = 175
-
Number of clinical features = 9
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.